3.4.22.B50	 In vivo assessment of equine arteritis virus vaccine improvement by disabling the deubiquitinase activity of papain-like protease 2	equine arteritis virus	
3.4.22.B50	 In vivo assessment of equine arteritis virus vaccine improvement by disabling the deubiquitinase activity of papain-like protease 2	equine arteritis virus Bucyrus	
3.4.22.B50	 Murine coronavirus ubiquitin-like domain is important for papain-like protease stability and viral pathogenesis	Murine coronavirus	
3.4.22.B50	 Porcine epidemic diarrhea virus papain-like protease 2 can be noncompetitively inhibited by 6-thioguanine	porcine epidemic diarrhea virus	
3.4.22.B50	Comparison of SARS and NL63 papain-like protease binding sites and binding site dynamics: inhibitor design implications	Human coronavirus NL63	
3.4.22.B50	Coronavirus papain-like endopeptidases	Alphacoronavirus	
3.4.22.B50	Deubiquitinase activity and regulation of antiviral innate immune responses by papain-like proteases of human coronavirus NL63	Human coronavirus NL63	
3.4.22.B50	Deubiquitinase function of arterivirus papain-like protease 2 suppresses the innate immune response in infected host cells	equine arteritis virus	
3.4.22.B50	Enhancement of proteolytic activity of a thermostable papain-like protease by structure-based rational design	Tabernaemontana divaricata	
3.4.22.B50	Expression of murine coronavirus recombinant papain-like proteinase: efficient cleavage is dependent on the lengths of both the substrate and the proteinase polypeptide	Murine coronavirus